satoreotide trizoxetan

PeptideexperimentalImaging agent

Clinical trial activity

3 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Sep 20, 2017 (NCT03220217)

Timeline

2010s

Jan 1, 2017
Earliest Phase 2 Sponsor(trial)
Jan 1, 2019
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Somatostatin receptorRadiopharmaceutical
Somatostatin receptor radiopharmaceutical

Chemistry & pharmacology

Loading structure…

SMILES

[68Ga+3].C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CC=C(NC(N)=O)C=C2)NC(=O)[C@H](CC3=CC=C(NC(=O)[C@@H]4CC(=O)NC(=O)N4)C=C3)NC(=O)[C@@H](CSSC[C@H](NC1=O)C(=O)N[C@H](CC5=CC=C(O)C=C5)C(N)=O)NC(=O)[C@H](CC6=CC=C(Cl)C=C6)NC(=O)CCC(N7CCN(CC([O-])=O)CCN(CC([O-])=O)CC7)C([O-])=O

Mol. weight: 1725.131 g/mol
Chirality: Racemic Mixture
Inorganic: No
Polymer: No
Multi-specific: No
Imaging: 68-Gallium

Oral

Parenteral

Topical

Sources

NCATSZP2ODR0UR3 ↗
ChEMBLCHEMBL4297532 ↗

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT03773133	Phase 1/Phase 2 (Phase 2)	May 15, 2019	Ipsen
NCT03697551	Phase 2	Nov 8, 2018	Ipsen
NCT03220217	Phase 2	Sep 20, 2017	Ipsen

Showing 3 of 3 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Ipsen	For profit	3	3	1	2017

1 organizations

Page 1 / 1